优特克单抗治疗斑块状银屑病疗效和安全性的荟萃分析 (1)

《优特克单抗治疗斑块状银屑病疗效和安全性的荟萃分析 (1)》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、山东大学硕士学位论文Efficacyandsafetyofustekinumabinpatientswithplaquepsoriasis：Ameta-analysisSpecialityDermatovenereologyPostgraduateShi-TongYANSupervisorProf．YingSUBackground：Psoriasisisacommon，chronicrelapsing／remittingimmune-mediatedskindiseasecharacterizedbyred，scalypatches，papules，andplaques

2、．Theskinlesionsseeninpsoriasismayvaryinseverityfromminorlocalizedpatchestocompletebodycoverage．Therearefourmaintypesofpsoriasis：plaque，guttate，pustularanderythrodermic．Plaquepsoriasisisthemostcommonform．Thecausesofpsoriasisarenotfullyunderstood．Itisgenerallyconsideredageneticdiseasethoug

3、httobetriggeredorinfluencedbyenvironmentalfactors．Becauseofrenal，hepatic，pulmonarytoxicityandlimitedefficacy,thelong—termuseoftraditionalsystemictherapiesisfrequentlyunacceptable．Recently,researchershavefocusedonthegeneticandimmunologicfeaturesofpsoriasis．Ustekinumab，afullyhumanmonoclona

4、lantibodydirectedagainstthesharedp40subunitofinterleukin(IL)-12andIL-23，wasdemonstratedtobehighlyefficaciousandgenerallywelltoleratedintreatingpatientswitllmoderatetoseverepsoriasis．TheoreticalrisksofpharmacologicblockadeofIL-12andIL-23includesusceptibilitytoinfectionandmalignancy．Inthis

5、article，wecollectedthepastpublishedrelatedresearchresultsathomeandabroad，conductedasystematicreviewofallrandomizedcontrolledtrials(RCTs)toevaluatetheefficacyandsafetyofustekinumabforpatientswithplaquepsoriasis．Objectives：Tosystematicallyreviewtheefficacyandsafetyofustekinumabonthesecondi

6、tionsinpatientswithplaquepsoriasis．Methods：ThePubMed，GoogleScholar,EMBASE，CochraneLibraryweresearched4山东大学硕士学位论文usingtheopenstrings“IL-12andIL-23andpsoriasis”-‘‘ABT-874andpsoriasis”，“IL．12／23monoclonalantibody”，“IL一12／23antibody","CNTO一1275"．SearcheswereupdatedtoDecember2013．Referencelis

7、tsofpriorreviews，systematicreviewsandtrialswerealSOchecked．Inclusioncriteria：randomizedcontrolledtrial，RCT；plaquepsoriasis；Ustekinumab．placebo．controlledtreatment；Thepropoaionofpatientswithatleast50％，75％，90％improvementinthepsoriasisareaandseverityindex(PASI50，PASI75，PASI9